Grifols SA announced on March 24, 2026, that its Board of Directors is considering an Initial Public Offering (IPO) for a portion of its U.S. Biopharma subsidiary, though completion depends on regulatory and market conditions. This move aims to enhance self-sufficiency in its Biopharma businesses.